Metamizole Kalceks (Metamizole Sodium Monohydrate)

Metamizole works by non‑selectively inhibiting cyclooxygenase enzymes (COX‑1 and COX‑2), which reduces prostaglandin production. Lower prostaglandin levels diminish nociceptive signaling and pyrogenic responses, while central analgesic and spasmolytic actions further contribute to pain relief and fever reduction.

The dose of Metamizole Kalceks is determined by the prescribing clinician based on the patient’s condition, severity of pain or fever, and clinical response. Healthcare professionals adjust the amount and frequency according to established medical guidelines.

Safety data for metamizole during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under direct medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Metamizole offers strong analgesic and antipyretic effects without the opioid‑related risks of dependence. Compared with traditional NSAIDs, it may have a lower incidence of gastrointestinal irritation but carries a rare risk of agranulocytosis. Choice of therapy depends on patient‑specific factors and risk‑benefit assessment.

Metamizole Kalceks should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or particulate.

The product is supplied as an injectable solution for intramuscular or intravenous administration by a qualified healthcare professional. The route, volume, and rate of injection are determined by the prescriber according to the clinical situation.

The most serious adverse reactions include agranulocytosis (a severe drop in white blood cells), anaphylactic shock, Stevens‑Johnson syndrome, and severe thrombocytopenia. Prompt medical attention is required if signs of infection, severe skin reactions, or allergic symptoms develop.

Metamizole Kalceks should be avoided in patients with known hypersensitivity to metamizole or other pyrazolones, those with existing severe bone‑marrow suppression, and individuals with a history of agranulocytosis. Caution is also advised for patients with severe liver or kidney impairment.